Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

16.50USD
25 Sep 2018
Change (% chg)

$-0.60 (-3.51%)
Prev Close
$17.10
Open
$17.20
Day's High
$17.50
Day's Low
$16.45
Volume
25,728
Avg. Vol
53,710
52-wk High
$20.55
52-wk Low
$10.25

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics Announces That FDA Accepts Elzonris Biologics License Application
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS ANNOUNCES THAT FDA ACCEPTS ELZONRIS™ BIOLOGICS LICENSE APPLICATION (BLA) AND GRANTS PRIORITY REVIEW.STEMLINE THERAPEUTICS INC - FDA ALSO GRANTED PRIORITY REVIEW FOR BLA AND HAS SET A TARGET ACTION DATE OF FEBRUARY 21, 2019, UNDER PDUFA.  Full Article

Stemline Therapeutics reports Q3 loss per share $0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.68.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Stemline Therapeutics-‍stemline ended Q3 of 2017 with $79.9 million in cash, cash equivalents and investments, as compared to $93.2 million as of June 30, 2017​.  Full Article

Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​.Stemline Therapeutics Inc - ‍based on feedback from U.S. FDA, co remains on track to begin submission of BLA in 4Q17-1Q18 timeframe for SL-401​.  Full Article

Stemline Therapeutics Q4 loss per share $0.56
Thursday, 16 Mar 2017 

Stemline Therapeutics Inc : Stemline therapeutics reports fourth quarter 2016 financial results . Q4 loss per share $0.56 . Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S .Qtrly grant revenue $299,401 versus $205,651.  Full Article